PA
AQST icon

PharVision Advisers’s Aquestive Therapeutics AQST Stock Holding History

PharVision Advisers’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-46,450
Closed -$260K – 694
2025
Q3 		$260K Buy
+46,450
New +$201K 0.15% 309

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PharVision Advisers's AQST Position: Q4 2025 in Review

PharVision Advisers sold out of Aquestive Therapeutics (AQST) in Q4 2025, closing a stake of 46,450 shares — an estimated $260K sold.

PharVision Advisers first reported a position in AQST in Q3 2025 and held it in 1 quarter. The position peaked at $260K in Q3 2025. 176 funds tracked by Wall St. Rank hold AQST as of Q4 2025.

  • PharVision Advisers reported no remaining Aquestive Therapeutics position as of Q4 2025 after selling out during the quarter.
  • PharVision Advisers sold 46,450 Aquestive Therapeutics shares in Q4 2025, an estimated $260K.
  • PharVision Advisers first reported a position in Aquestive Therapeutics in Q3 2025 and held it in 1 quarter.
  • PharVision Advisers's Aquestive Therapeutics position peaked at $260K in Q3 2025.
  • 176 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.